Nicola Gökbuget Selected Research

blinatumomab

1/2021	Long-term follow-up of blinatumomab in patients with relapsed/refractory Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukaemia: Final analysis of ALCANTARA study.
1/2021	Blinatumomab as first salvage versus second or later salvage in adults with relapsed/refractory B-cell precursor acute lymphoblastic leukemia: Results of a pooled analysis.
1/2021	Long-term survival of patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab.
11/2020	Curative outcomes following blinatumomab in adults with minimal residual disease B-cell precursor acute lymphoblastic leukemia.
4/2020	Blinatumomab vs historic standard-of-care treatment for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukaemia.
12/2019	Transplantation in adults with relapsed/refractory acute lymphoblastic leukemia who are treated with blinatumomab from a phase 3 study.
10/2019	Molecular response with blinatumomab in relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
1/2019	Blinatumomab for Acute Lymphoblastic Leukemia Relapse after Allogeneic Hematopoietic Stem Cell Transplantation.
1/2018	Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia.
11/2017	Hematopoietic stem cell involvement in BCR-ABL1-positive ALL as a potential mechanism of resistance to blinatumomab therapy.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Nicola Gökbuget Research Topics

Disease

60	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2022 - 10/2002
25	Residual Neoplasm 01/2022 - 12/2002
15	Leukemia 01/2020 - 10/2002
14	Philadelphia Chromosome 01/2021 - 10/2002
12	Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (T-ALL) 02/2015 - 04/2004
8	Burkitt Lymphoma (Burkitt's Lymphoma) 12/2014 - 04/2004
4	Cytokine Release Syndrome 01/2021 - 12/2015
4	Neoplasms (Cancer) 01/2021 - 01/2009
4	Non-Hodgkin Lymphoma (Lymphosarcoma) 03/2012 - 12/2002
3	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 05/2006 - 10/2002
2	Bites and Stings (Sting) 01/2021 - 06/2012
2	Genetic Translocation (Chromosomal Translocation) 08/2013 - 03/2012
2	Lymphoma (Lymphomas) 09/2011 - 02/2011
2	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 02/2011 - 05/2006
1	Hypersensitivity (Allergy) 01/2022
1	Hypertension (High Blood Pressure) 04/2021
1	Sepsis (Septicemia) 04/2021
1	Hypertriglyceridemia 04/2021
1	Pain (Aches) 04/2021
1	Osteonecrosis (Kienbock's Disease) 04/2021
1	Hypercholesterolemia 04/2021
1	Infections 01/2021
1	Febrile Neutropenia 01/2021
1	Aneuploidy (Aneuploid) 12/2019
1	Graft vs Host Disease (Graft-Versus-Host Disease) 01/2019
1	Mycoses (Diseases, Fungus) 01/2017
1	Invasive Fungal Infections 01/2017
1	Liver Diseases (Liver Disease) 08/2016
1	Clinical Deterioration 11/2013
1	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 08/2013
1	Hydrocephalus (Hydrocephaly) 02/2010
1	Hepatomegaly 01/2010
1	Splenomegaly 01/2010
1	Pathologic Complete Response 01/2009
1	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 05/2006
1	Adult T-Cell Leukemia-Lymphoma (Leukemia Lymphoma, T Cell, Acute, HTLV I Associated) 04/2004
1	Blast Crisis (Blast Phase) 10/2003
1	Hematologic Neoplasms (Hematological Malignancy) 10/2002

Drug/Important Bio-Agent (IBA)

20	blinatumomabIBA 01/2021 - 06/2011
9	Inotuzumab OzogamicinIBA 01/2021 - 08/2016
6	Rituximab (Mabthera)FDA Link 12/2014 - 04/2004
5	Imatinib Mesylate (Gleevec)FDA Link 01/2009 - 10/2002
4	Asparaginase (Elspar)FDA Link 01/2022 - 01/2020
4	Tyrosine Kinase InhibitorsIBA 06/2017 - 10/2002
4	Messenger RNA (mRNA)IBA 12/2009 - 11/2006
3	CalicheamicinsIBA 01/2019 - 08/2016
3	RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA 01/2018 - 08/2007
3	Transcription Factors (Transcription Factor)IBA 10/2017 - 10/2006
2	AntibodiesIBA 01/2022 - 06/2011
2	RNA (Ribonucleic Acid)IBA 12/2019 - 01/2019
2	Monoclonal AntibodiesIBA 01/2017 - 04/2004
2	Pharmaceutical PreparationsIBA 09/2011 - 10/2002
2	Proto-Oncogene Proteins c-etsIBA 02/2011 - 10/2006
1	Immunoglobulin G (IgG)IBA 01/2022
1	Casein Kinase II (Casein Kinase 2)IBA 12/2021
1	venetoclaxIBA 12/2021
1	Indicators and Reagents (Reagents)IBA 01/2020
1	TOR Serine-Threonine KinasesIBA 01/2020
1	dactolisibIBA 01/2020
1	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 01/2020
1	Phosphatidylinositol 3-Kinases (PI 3 Kinase)IBA 01/2020
1	ProteomeIBA 12/2019
1	CytokinesIBA 12/2019
1	DNA (Deoxyribonucleic Acid)IBA 12/2019
1	Immunoconjugates (Immunoconjugate)IBA 01/2019
1	CI 22IBA 06/2017
1	liposomal amphotericin B FDA Link 01/2017
1	Amyloid Precursor Protein Secretases (beta-Secretase)IBA 02/2015
1	Janus Kinase InhibitorsIBA 02/2015
1	Immunoglobulin Heavy Chains (Immunoglobulin Heavy Chain)IBA 08/2013
1	IgKIBA 03/2012
1	nelarabine (506U78)FDA Link 09/2011
1	purineIBA 09/2011
1	CD19 AntigensIBA 06/2011
1	Cytarabine (Cytosar-U)FDA LinkGeneric 02/2011
1	MicroRNAs (MicroRNA)IBA 02/2011
1	Interleukin-15 (Interleukin 15)IBA 01/2010
1	Multidrug Resistance-Associated ProteinsIBA 12/2009
1	Biological ProductsIBA 12/2002
1	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 10/2002
1	Proteins (Proteins, Gene)FDA Link 10/2002
1	TransferasesIBA 10/2002
1	Interferon-alpha (Interferon Alfa)IBA 10/2002

Therapy/Procedure

29	Therapeutics 01/2022 - 10/2002
19	Drug Therapy (Chemotherapy) 01/2020 - 12/2002
9	Stem Cell Transplantation 12/2019 - 05/2003
8	Hematopoietic Stem Cell Transplantation 04/2021 - 10/2014
4	Salvage Therapy 12/2021 - 01/2015
3	Transplantation 12/2019 - 01/2009
1	Complementary Therapies (Alternative Medicine) 01/2019
1	Immunotherapy 01/2019
1	Aftercare (After-Treatment) 01/2018
1	Remission Induction 01/2017
1	Consolidation Chemotherapy 08/2012
1	Transcutaneous Electric Nerve Stimulation (TENS) 01/2011
1	Induction Chemotherapy 02/2010
1	Homologous Transplantation 01/2009
1	Combination Drug Therapy (Combination Chemotherapy) 01/2009
1	Cranial Irradiation 10/2003